Fiche centre
Duke University Health System
Durham — United States
Essais liés9clinical trials
VilleDurhamlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07686692
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Secukinumab Injection | Cancer | Phase 1 | NCT07237594 | IL-17 Blockade to Decrease irAEs (REPLAY) | RECRUITING |
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Dreem headband | Épilepsie | Non applicable | NCT06545643 | Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs | RECRUITING |
| Ferric derisomaltose | Insuffisance cardiaque | Phase 4 | NCT07686692 | INFUSE-HFpEF — IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency | NOT_YET_RECRUITING |
| Hemanext ONE system | Cancer | Non applicable | NCT06685848 | Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion | ACTIVE_NOT_RECRUITING |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | ACTIVE_NOT_RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |
| ANT recording and stimulation | Épilepsie | NA | NCT04102254 | Thalamic Stimulation for Epilepsy Study | WITHDRAWN |